Who owns Wegovy — and why does it matter for your treatment?

You've searched 'Wegovy owned by', here's the straightforward answer, and why it changes how you buy

Picture this: you've seen Wegovy mentioned in a news article, a friend is already using it, and you want to know exactly who you're dealing with before you commit to a treatment. That's a sensible instinct. Wegovy is manufactured and marketed by Novo Nordisk, a company founded in Denmark in 1923 whose entire history has been built around metabolic medicine. They hold the UK marketing authorisation for Wegovy, which means they are the legal entity responsible to the MHRA for its safety profile, its manufacturing standards, and the accuracy of its Patient Information Leaflet.

Novo Nordisk also makes Ozempic, the same active ingredient (semaglutide) but licensed in the UK for type 2 diabetes, not for weight management. That distinction matters. You can read more about how semaglutide works across these different contexts on our semaglutide overview page. Knowing the manufacturer helps you spot who genuinely sits in that supply chain and who does not.

A question our prescribers hear most weeks is whether Wegovy bought from a social-media seller is the same product you'd get from a regulated pharmacy. It isn't, not reliably. The MHRA has warned publicly about counterfeit weight-loss pens, and the only way to be certain a pen left Novo Nordisk's authorised supply chain intact is to obtain it via a prescription from a GPhC-registered pharmacy.

What Novo Nordisk's ownership tells you about Wegovy's UK licence and supply

Novo Nordisk holds a UK marketing authorisation for Wegovy as a once-weekly subcutaneous injection, licensed for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as high blood pressure or type 2 diabetes. Because the company holds that authorisation, any pharmacy dispensing Wegovy in the UK must source it through Novo Nordisk's authorised distribution network, not grey markets, not overseas repackaging, not unverified third-party wholesalers.

The company has also been responsible for developing higher-dose presentations. In January 2026 a 7.2mg maintenance dose gained UK regulatory approval, and in April 2026 the MHRA approved a dedicated single-dose 7.2mg pen, a meaningful step up from the previous 2.4mg weekly injection. These developments sit within Novo Nordisk's clinical programme and feed directly into how prescribers now discuss maintenance options with patients. For detail on how the treatment progresses from starting dose to maintenance, the week-by-week Wegovy guide sets this out clearly.

Novo Nordisk's accountability to UK regulators also means that if a safety signal emerges post-launch, it is the company's legal obligation to report it, update the prescribing information, and communicate with pharmacies and clinicians. That chain of accountability is absent when a medicine is obtained from an unlicensed seller.

How manufacturer ownership sits within the bigger picture of cost and access

Novo Nordisk sets the ex-manufacturer list price for Wegovy in the UK. In the private market, pharmacies add their own costs (consultation, prescription, dispensing, delivery) which is why prices vary between providers. Our Wegovy cost page explains what drives private pricing and what a transparent all-in price should include. Eli Lilly, who own Mounjaro (tirzepatide), operate the same model on the tirzepatide side; the two companies are the principal manufacturers in this treatment category and are the ones authorised to supply UK pharmacies through the licensed supply chain.

On the NHS, Wegovy is recommended by NICE (under NICE technology appraisal TA875) for use within specialist weight management services, subject to strict eligibility criteria and a maximum treatment duration of two years. Novo Nordisk's role there is to supply agreed volumes through NHS procurement; the clinical decisions still rest with the prescriber. Privately, the route is faster: a regulated online pharmacy can complete a consultation, prescribe, and dispatch without the waiting lists attached to NHS specialist services. Our weight-loss treatment overview covers the options side by side.

If you're comparing Wegovy with tirzepatide (Mounjaro) (from Eli Lilly) our Wegovy pillar page and the guide to obtaining Wegovy through a UK pharmacy both cover what to expect and how the two medicines differ clinically. The who owns Wegovy question often comes up alongside curiosity about where and how Wegovy is made, both pages sit in the same series.

For anyone ready to find out whether they're clinically suitable for a GLP-1 medicine, the next step is a consultation with a prescriber, not a search for the cheapest listing. You can check your eligibility with our clinical team, no referral required, and every consultation is reviewed the same day by a real prescriber.